Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Cells in the body have to move around in order to do their jobs. During development, for instance, cells are distributed to ...

The research focuses on cells’ “feet,” which are small bundles of molecules that help cells move. Scientists are exploring ...

A bill that would ban the use of mRNA vaccines, including for Covid-19, is on its way to the House floor after passing out of committee in a party-line vote Wednesday. Sponsored by Rep. Greg Kmetz, ...

Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...